{"id":"mtor","name":"mTOR","symbol":"MTOR","route":"/targets/mtor/","asOf":"2026-09-10","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3942","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198793","uniprot":"https://www.uniprot.org/uniprotkb/P42345/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P42345","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2842","open-targets":"https://platform.opentargets.org/target/ENSG00000198793","civic":"https://civicdb.org/genes/2475/summary","oncokb":"https://www.oncokb.org/gene/MTOR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MTOR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MTOR","depmap":"https://depmap.org/portal/gene/MTOR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000198793-MTOR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2475","omim":"https://www.omim.org/entry/601231"}],"products":[{"id":"sapanisertib","name":"Sapanisertib","status":"phase-2","modality":"small molecule","route":"/drugs/sapanisertib/"},{"id":"sirolimus","name":"Sirolimus","status":"approved","modality":"Oral mammalian target of rapamycin (mTOR) inhibitor, used as an immunosuppressant","route":"/drugs/sirolimus/"},{"id":"sirolimus-albumin-bound","name":"Sirolimus protein-bound particles","status":"approved","modality":"Albumin-bound mTOR inhibitor (intravenous)","route":"/drugs/sirolimus-albumin-bound/"}],"trials":[{"id":"tumorapa","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","nct":"NCT00133887","phase":"3","status":"positive"},{"id":"nct04736589","name":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","nct":"NCT04736589","phase":"3","status":"planned"},{"id":"ampect","name":"AMPECT","nct":"NCT02494570","phase":"2","status":"positive"},{"id":"nct05103358","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","nct":"NCT05103358","phase":"2","status":"active"},{"id":"nct06463028","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","nct":"NCT06463028","phase":"2","status":"recruiting"},{"id":"nct05997017","name":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","nct":"NCT05997017","phase":"2","status":"recruiting"},{"id":"nct07558733","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","nct":"NCT07558733","phase":"1/2","status":"recruiting"}],"pathways":["choline-metabolism-in-cancer","hepatocellular-carcinoma-signalling","renal-cell-carcinoma-signalling"],"companies":["aadi-bioscience","takeda"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}